跳至主要内容
临床试验/NCT00046995
NCT00046995Unknown3 期

5-Fluorouracil-Leucovorin With or Without Carboplatin as Adjuvant Treatment for Primary Dukes B2-C Colon Cancer; Chronomodulated Versus Standard Administration. A Multicenter Randomized Phase III Trial of the GRECCR-Belgium (Study 03).

Groupe Regional d'Etudes du Cancer Colorectal4 个研究点 分布在 1 个国家目标入组 800 人开始时间: 2001年5月1日最近更新:
适应症
相关药物

试验速览

阶段
3 期
发起方
入组人数
800
试验地点
4
主要终点
Disease-free survival

研究概览

简要总结

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which schedule of chemotherapy is most effective in treating colon cancer.

PURPOSE: Randomized phase III trial to compare different schedules of chemotherapy using carboplatin with fluorouracil and leucovorin in treating patients who have stage IIB or stage III colon cancer.

详细描述

OBJECTIVES:

  • Compare the disease-free survival of patients with completely resected stage IIB or III colon cancer treated with adjuvant chronomodulated vs standard schedule fluorouracil and leucovorin calcium with or without carboplatin.
  • Compare the overall survival of patients treated with these regimens.
  • Compare the toxicity of these regimens in these patients.
  • Compare the quality of life of patients treated with these regimens.
  • Determine the dose intensities of fluorouracil and carboplatin in these patients.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to participating center and disease stage (IIB vs III). Patients are randomized to 1 of 4 treatment arms.

  • Arm I (standard schedule): Patients receive fluorouracil (5-FU) IV continuously and leucovorin calcium (CF) IV on days 1 and 2.
  • Arm II (standard + carboplatin schedule): Patients receive 5-FU and CF as in arm I plus carboplatin IV on day 1.
  • Arm III (chronomodulated schedule): Patients receive 5-FU IV continuously and CF IV continuously on days 1-4.
  • Arm IV (chronomodulated + carboplatin schedule): Patients receive 5-FU and CF as in arm III plus carboplatin IV continuously on days 1-4.

Quality of life is assessed.

研究设计

研究类型
Interventional
分配方式
Randomized
主要目的
Treatment

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • DISEASE CHARACTERISTICS:
  • Histologically confirmed adenocarcinoma of the colon
  • Stage IIB or III (Dukes stage B2 or C)
  • Complete curative resection performed within the past 7 weeks (negative margins)
  • No local or regional relapsed disease
  • Tumor more than 15 cm above the anal margin
  • Carcinoembryonic antigen less than 5 ng/mL (after surgery)
  • No rectal cancer
  • No metastatic disease
  • PATIENT CHARACTERISTICS:
  • 18 and over
  • Performance status
  • ECOG 0-1 OR
  • Karnofsky 60-100%
  • Life expectancy
  • Not specified
  • Hematopoietic
  • Neutrophil count at least 2,000/mm3
  • Platelet count at least 100,000/mm3
  • Bilirubin no greater than 1.5 times upper limit of normal (ULN)
  • SGOT and SGPT no greater than 5 times ULN
  • Creatinine no greater than 1.5 times ULN
  • Cardiovascular
  • No serious coronary disease
  • Not pregnant
  • Fertile patients must use effective contraception
  • No concurrent infectious disease
  • No other malignancy except adequately treated basal cell skin cancer or carcinoma in situ of the cervix
  • PRIOR CONCURRENT THERAPY:
  • Biologic therapy
  • No prior immunotherapy
  • Chemotherapy
  • No prior chemotherapy
  • Endocrine therapy
  • Not specified
  • Radiotherapy
  • No prior radiotherapy (before or after surgery)
  • See Disease Characteristics
  • No concurrent participation in another clinical trial

排除标准

  • 未提供

结局指标

主要结局

Disease-free survival

次要结局

  • Quality of life
  • Tolerability

研究者

发起方
Groupe Regional d'Etudes du Cancer Colorectal
申办方类型
Other

研究点 (4)

Loading locations...

相似试验